Maxim Group analyst Naureen Quibria reiterated a Buy rating on Fennec Pharmaceuticals (FENC – Research Report) yesterday and set a price target of $12.00. The company’s shares closed last Friday at $7.37.
Quibria has an average return of 11.4% when recommending Fennec Pharmaceuticals.
According to TipRanks.com, Quibria is ranked #3044 out of 7535 analysts.
Fennec Pharmaceuticals has an analyst consensus of Moderate Buy, with a price target consensus of $14.50.
Based on Fennec Pharmaceuticals’ latest earnings release for the quarter ending March 31, the company reported a quarterly GAAP net loss of $4.73 million. In comparison, last year the company had a GAAP net loss of $3.83 million.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
Fennec Pharmaceuticals, Inc. operates as a biopharmaceutical company. It engages in the development of sodium thiosulfate for the prevention of ototoxicity from cisplatin in pediatric cancer patients. The company was founded by Orest W. Blaschuk on September 3, 1996 and is headquartered in Durham, NC.